Bicyclic amides as kinase inhibitors

The disclosure relates to bicyclic amides such as 6-(6-Hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethylphenyl)-amide, or a tautomer thereof, or a salt thereof, which are suitable in the treatment of a protein kinase dependent disease selected from ocular neovascularisation, diabetic retinopathy, age-related macular degeneration, psoriasis, Von Hippel Lindau disease, hemangioblastoma, angioma, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, transplant rejection, glomerulonephritis, mesangioproliferative glomerulonephritis, haemolytic-uraemic syndrome, hypertensive nephrosclerosis, atheroma, arterial restenosis, autoimmune disease, acute inflammation, hepatic cirrhosis, diabetes, endometriosis, chronic asthma, arterial or post-transplantational atherosclerosis, neurodegenerative disorders, leukemias, breast cancer, adenocarcinoma, colorectal cancer, lung cancer, renal cancer, liver cancer, pancreatic cancer, ovarian cancer, cancer of the prostate, myeloma, multiple myeloma, myelodysplastic syndrome, AML (acute myeloid leukemia), AMM (agnogenic myeloid metaplasia), mesothelioma, glioma and/or glioblastoma.